Denali Therapeutics Equity 2024

Denali Therapeutics Aktienanalyse

What does Denali Therapeutics do?

Denali Therapeutics Inc is a biotechnology company specializing in the research and development of therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2015 by four former employees of Genentech, with the goal of finding innovative treatments for serious neurological conditions. Denali Therapeutics' business model is based on a patented platform technology that allows the company to target and deliver its drugs precisely to the brain of patients. The company utilizes "liposomes," microscopic bubbles of fat that are loaded with the drug and then transported to the brain through the bloodstream. Denali Therapeutics is divided into three divisions: development platform, therapy development, and diagnosis development. The development platform is the core business of Denali Therapeutics. Here, the company continues to develop its liposome technology to be used for various neurological diseases. The therapy development focuses on developing targeted drugs for specific neurodegenerative diseases. Denali Therapeutics collaborates closely with neurologists and other experts to develop the best possible therapies for patients. The diagnosis development aims to detect early symptoms of neurodegenerative diseases, enabling early diagnosis and treatment. Denali Therapeutics is primarily working on the development of testing methods that will allow for early detection of Alzheimer's and Parkinson's. Currently, Denali Therapeutics has several promising drugs in its pipeline. One of the most important projects is a drug for Alzheimer's disease, which is currently being tested in clinical trials. The drug targets the accumulation of beta-amyloid, which is responsible for the progression of the disease. Another promising project is a drug for Parkinson's, which is also being tested in clinical trials. The drug targets the accumulation of alpha-synuclein, a protein implicated in the development of Parkinson's. Denali Therapeutics aims to develop new therapies for neurodegenerative diseases to improve the lives of patients. The company is committed to answering the many unanswered medical questions in the field of neurology and making a contribution to overcoming these serious diseases. Denali Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Denali Therapeutics's Equity

Denali Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Denali Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Denali Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Denali Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Denali Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Denali Therapeutics Stock

What is the equity of Denali Therapeutics this year?

Denali Therapeutics has equity of 1.03 B USD this year.

What was the equity of Denali Therapeutics compared to the previous year?

The equity of Denali Therapeutics has increased/decreased by -1.1% decreased compared to the previous year.

What impact does a high equity have on investors of Denali Therapeutics?

A high equity is advantageous for investors of Denali Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Denali Therapeutics?

A low equity can be a risk for investors of Denali Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Denali Therapeutics affect the company?

An increase in equity of Denali Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Denali Therapeutics affect the company?

A reduction in equity of Denali Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Denali Therapeutics?

Some factors that can affect the equity of Denali Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Denali Therapeutics so important for investors?

The equity of Denali Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Denali Therapeutics take to change the equity?

To change equity, Denali Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Denali Therapeutics pay?

Over the past 12 months, Denali Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Denali Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Denali Therapeutics?

The current dividend yield of Denali Therapeutics is .

When does Denali Therapeutics pay dividends?

Denali Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Denali Therapeutics?

Denali Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Denali Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Denali Therapeutics located?

Denali Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Denali Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Denali Therapeutics from 6/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did Denali Therapeutics pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of Denali Therapeutics in the year 2023?

In the year 2023, Denali Therapeutics distributed 0 USD as dividends.

In which currency does Denali Therapeutics pay out the dividend?

The dividends of Denali Therapeutics are distributed in USD.